title: EGFR and NF-κB: partners in cancer.
abstract: Oncogenic proteins cooperate to promote tumor development and progression by sustaining cell proliferation, survival and invasiveness. Constitutive epidermal growth factor receptor (EGFR) and nuclear factor κb (NF-κB) activities are seen in multiple solid tumors and combine to provide oncogenic signals to cancer cells. Understanding how these oncogenic pathways are connected is crucial, given their role in intrinsic or acquired resistance to targeted anticancer therapies. We review molecular mechanisms by which both EGFR- and NF-κB-dependent pathways establish positive loops to increase their oncogenic potential. We also describe how NF-κB promotes resistance to EGFR inhibitors.
authors.affiliation: Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Centre Hospitalier Universitaire (CHU), Sart-Tilman, Liege, Belgium; Laboratory of Medical Chemistry, University of Liege, CHU, Sart-Tilman, Liege, Belgium; GIGA-Signal Transduction, University of Liege, CHU, Sart-Tilman, Liege, Belgium.
authors.forename: Kateryna
authors.initials: K
authors.lastname: Shostak
authors.affiliation: Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Centre Hospitalier Universitaire (CHU), Sart-Tilman, Liege, Belgium; Laboratory of Medical Chemistry, University of Liege, CHU, Sart-Tilman, Liege, Belgium; GIGA-Signal Transduction, University of Liege, CHU, Sart-Tilman, Liege, Belgium; Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavre, Belgium. Electronic address: Alain.chariot@ulg.ac.be.
authors.forename: Alain
authors.initials: A
authors.lastname: Chariot
mesh_terms: D000818:Animals; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology*; D000069347:Erlotinib Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use; D000077156:Gefitinib; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006821:Hyaluronoglucosaminidase; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011506:Proteins / Q000276:immunology; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D011506:Proteins; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; C491433:CEMIP protein, human; D006821:Hyaluronoglucosaminidase; D000077156:Gefitinib
keywords: EGFR; NF-κB; erlotinib; gefitinib; resistance; tumor-initiating cells